# Mezigdomide

Source: https://onco.cc/drugs/mezigdomide/  
OnCo record `mezigdomide` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Mezigdomide is the most potent oral cereblon modulator, producing responses in about 40% of triple-class-refractory myeloma with dexamethasone alone.

## Summary

Mezigdomide is the most potent oral cereblon E3 ligase modulator (CELMoD) in development, producing rapid and deep degradation of Ikaros and Aiolos with strong T-cell co-stimulation. In CC-92480-MM-001, mezigdomide with dexamethasone alone produced an ORR of 41% in heavily pretreated, triple-class-refractory myeloma, including responses in 30% of patients with extramedullary disease, a group that responds poorly to most therapies. Two phase 3 trials are ongoing: SUCCESSOR-1 compares Mezi-Vd with Pom-Vd, and SUCCESSOR-2 compares Mezi-Kd with Kd. The open questions are durability of response and whether cytopenias and infections limit its use in combination. BMS develops it alongside the related CELMoD iberdomide. It is a pill that acts on the same target as lenalidomide but strongly enough to work when that drug and its successors have failed.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-07
- Code: CC-92480
- Modality: CELMoD (cereblon E3 ligase modulator)
- Mechanism: High-affinity cereblon modulator; rapid, deep Ikaros/Aiolos degradation with strong T-cell co-stimulation.

## Sources

- ClinicalTrials.gov: trials of Mezigdomide: https://clinicaltrials.gov/search?intr=CC-92480

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/), [Relapsed or refractory multiple myeloma](https://onco.cc/cancers/myeloma-relapsed-refractory/)
- technologies: [Cereblon E3 ligase modulators (CELMoDs)](https://onco.cc/technologies/celmods/), [PROTACs & molecular glues (targeted protein degradation)](https://onco.cc/technologies/protac-degrader/)
- companies: [Bristol Myers Squibb](https://onco.cc/companies/bms/)
- trials: [A Study to Assess Change in Disease Activity and Adverse Events (AE)s in Adult Participants With Multiple Myeloma Receiving T Cell Engaging Bi/Tri-spe](https://onco.cc/trials/nct06892522/), [A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Tre](https://onco.cc/trials/nct03989414/), [A Study to Determine the Recommended Dose and Schedule, and Evaluate the Safety and Preliminary Efficacy of Mezigdomide in Combination With Elranatama](https://onco.cc/trials/nct06988488/), [A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants W](https://onco.cc/trials/nct05552976/), [A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Re](https://onco.cc/trials/nct05519085/), [A Study to Evaluate Safety, Drug Levels and Effectiveness of CC-92480 (BMS-986348) in Combination With Other Treatments in Participants With Relapsed ](https://onco.cc/trials/nct05372354/)
- pathways: [Ubiquitin-proteasome system & protein homeostasis](https://onco.cc/pathways/ubiquitin-proteasome-system/)

---
JSON: https://onco.cc/api/v1/entities/mezigdomide.json